Elbow Dysplasia and subsequent Osteoarthritis (OA) is one of the leading causes of chronic pain in dogs. Arthramid® is an innovative soft hydrogel (2.5% iPAAG®) injected directly into the affected joint, where it integrates into the joint lining to restore joint function, reduce pain, and improve mobility.
Not all dogs with stiffness or lameness caused by dysplasia have osteoarthritis, but many do. Early treatment can significantly improve quality of life. A veterinarian can assess whether Arthramid® is suitable based on your dog’s symptoms and joint health.
Arthramid® is not a surgical repair, but treats OA at its source, reducing synovial inflammation, improves joint stability, and supports better longterm comfort, making it a valuable option for many dogs with elbow dysplasia-related lameness.
Joint lameness often develops gradually, but starts at an early age, and elbow dysplasia may go unnoticed until your dog shows pain during activity, difficulty getting up, or intermittent limping. The sooner it’s assessed, the better the long-term outcome.
A veterinarian can determine whether Arthramid® is appropriate based on your dog’s joint health, lameness pattern, and diagnostic imaging.
Trial Eligibility Criteria
We’ll contact you within one business day to help determine whether Arthramid® may benefit your dog.
NOTE: ArthramidVet® is a registered S4 for the treatment of lameness in horses (APVMA No. 86728/ ACVM No. A11596). Use in non-equine species in Australia and New Zealand is currently extra-label and at the veterinarian’s discretion.